Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Brikell, I, Wimberley, T, Albiñana, C, Pedersen, EM, Vilhjálmsson, BJ, Agerbo, E, Demontis, D, Børglum, AD, Schork, AJ, LaBianca, S, Werge, T, Mors, O, Hougaard, DM, Thapar, A, Mortensen, PB & Dalsgaard, S 2021, 'Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD', The American journal of psychiatry, bind 178, nr. 9, s. 854-864. https://doi.org/10.1176/appi.ajp.2020.20121686

APA

Brikell, I., Wimberley, T., Albiñana, C., Pedersen, E. M., Vilhjálmsson, B. J., Agerbo, E., Demontis, D., Børglum, A. D., Schork, A. J., LaBianca, S., Werge, T., Mors, O., Hougaard, D. M., Thapar, A., Mortensen, P. B., & Dalsgaard, S. (2021). Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. The American journal of psychiatry, 178(9), 854-864. https://doi.org/10.1176/appi.ajp.2020.20121686

CBE

Brikell I, Wimberley T, Albiñana C, Pedersen EM, Vilhjálmsson BJ, Agerbo E, Demontis D, Børglum AD, Schork AJ, LaBianca S, Werge T, Mors O, Hougaard DM, Thapar A, Mortensen PB, Dalsgaard S. 2021. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. The American journal of psychiatry. 178(9):854-864. https://doi.org/10.1176/appi.ajp.2020.20121686

MLA

Vancouver

Author

Brikell, Isabell ; Wimberley, Theresa ; Albiñana, Clara ; Pedersen, Emil Michael ; Vilhjálmsson, Bjarni Jóhann ; Agerbo, Esben ; Demontis, Ditte ; Børglum, Anders D ; Schork, Andrew J ; LaBianca, Sonja ; Werge, Thomas ; Mors, Ole ; Hougaard, David M ; Thapar, Anita ; Mortensen, Preben Bo ; Dalsgaard, Søren. / Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. I: The American journal of psychiatry. 2021 ; Bind 178, Nr. 9. s. 854-864.

Bibtex

@article{ba8dddb418eb4ce8bf251e3af86c5b26,
title = "Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD",
abstract = "OBJECTIVE: Stimulant medications are effective for treating attention deficit hyperactivity disorder (ADHD), yet discontinuation and switch to nonstimulant ADHD medications are common. This study aimed to identify genetic, clinical, and sociodemographic factors influencing stimulant treatment initiation, discontinuation, and switch to nonstimulants in individuals with ADHD.METHODS: The authors obtained genetic and national register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample and defined stimulant treatment initiation, discontinuation, and switch from prescriptions. For each stimulant treatment outcome, they examined associations with polygenic risk scores (PRSs) for psychiatric disorders and clinical and sociodemographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated single-nucleotide polymorphism heritability (h2SNP).RESULTS: Eighty-one percent of the sample initiated stimulant treatment. Within 2 years, 45% discontinued stimulants and 15% switched to nonstimulants. Bipolar disorder PRS (hazard ratio=1.05, 95% CI=1.02, 1.09) and schizophrenia PRS (hazard ratio=1.07, 95% CI=1.03, 1.11) were associated with discontinuation. Depression, bipolar disorder, and schizophrenia PRSs were marginally but not significantly associated with switch (hazard ratio range, 1.05-1.07). No associations were observed for ADHD and autism PRSs. Individuals diagnosed with ADHD at age 13 or older had higher rates of stimulant initiation, discontinuation, and switch (hazard ratio range, 1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (hazard ratio range, 0.84-0.88) and increased rates of discontinuation (hazard ratio range, 1.19-1.45) and switch (hazard ratio range, 1.40-2.08). h2SNP estimates were not significantly different from zero. No GWAS hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch.CONCLUSIONS: The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.",
keywords = "Adolescent, Adult, Attention Deficit Disorder with Hyperactivity/complications, Central Nervous System Stimulants/therapeutic use, Child, Child, Preschool, Comorbidity, Demography, Female, Genome-Wide Association Study, Humans, Male, Mental Disorders/complications, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Risk Factors, Social Factors, Treatment Outcome, Young Adult",
author = "Isabell Brikell and Theresa Wimberley and Clara Albi{\~n}ana and Pedersen, {Emil Michael} and Vilhj{\'a}lmsson, {Bjarni J{\'o}hann} and Esben Agerbo and Ditte Demontis and B{\o}rglum, {Anders D} and Schork, {Andrew J} and Sonja LaBianca and Thomas Werge and Ole Mors and Hougaard, {David M} and Anita Thapar and Mortensen, {Preben Bo} and S{\o}ren Dalsgaard",
year = "2021",
month = sep,
doi = "10.1176/appi.ajp.2020.20121686",
language = "English",
volume = "178",
pages = "854--864",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Publishing, Inc",
number = "9",

}

RIS

TY - JOUR

T1 - Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD

AU - Brikell, Isabell

AU - Wimberley, Theresa

AU - Albiñana, Clara

AU - Pedersen, Emil Michael

AU - Vilhjálmsson, Bjarni Jóhann

AU - Agerbo, Esben

AU - Demontis, Ditte

AU - Børglum, Anders D

AU - Schork, Andrew J

AU - LaBianca, Sonja

AU - Werge, Thomas

AU - Mors, Ole

AU - Hougaard, David M

AU - Thapar, Anita

AU - Mortensen, Preben Bo

AU - Dalsgaard, Søren

PY - 2021/9

Y1 - 2021/9

N2 - OBJECTIVE: Stimulant medications are effective for treating attention deficit hyperactivity disorder (ADHD), yet discontinuation and switch to nonstimulant ADHD medications are common. This study aimed to identify genetic, clinical, and sociodemographic factors influencing stimulant treatment initiation, discontinuation, and switch to nonstimulants in individuals with ADHD.METHODS: The authors obtained genetic and national register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample and defined stimulant treatment initiation, discontinuation, and switch from prescriptions. For each stimulant treatment outcome, they examined associations with polygenic risk scores (PRSs) for psychiatric disorders and clinical and sociodemographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated single-nucleotide polymorphism heritability (h2SNP).RESULTS: Eighty-one percent of the sample initiated stimulant treatment. Within 2 years, 45% discontinued stimulants and 15% switched to nonstimulants. Bipolar disorder PRS (hazard ratio=1.05, 95% CI=1.02, 1.09) and schizophrenia PRS (hazard ratio=1.07, 95% CI=1.03, 1.11) were associated with discontinuation. Depression, bipolar disorder, and schizophrenia PRSs were marginally but not significantly associated with switch (hazard ratio range, 1.05-1.07). No associations were observed for ADHD and autism PRSs. Individuals diagnosed with ADHD at age 13 or older had higher rates of stimulant initiation, discontinuation, and switch (hazard ratio range, 1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (hazard ratio range, 0.84-0.88) and increased rates of discontinuation (hazard ratio range, 1.19-1.45) and switch (hazard ratio range, 1.40-2.08). h2SNP estimates were not significantly different from zero. No GWAS hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch.CONCLUSIONS: The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.

AB - OBJECTIVE: Stimulant medications are effective for treating attention deficit hyperactivity disorder (ADHD), yet discontinuation and switch to nonstimulant ADHD medications are common. This study aimed to identify genetic, clinical, and sociodemographic factors influencing stimulant treatment initiation, discontinuation, and switch to nonstimulants in individuals with ADHD.METHODS: The authors obtained genetic and national register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample and defined stimulant treatment initiation, discontinuation, and switch from prescriptions. For each stimulant treatment outcome, they examined associations with polygenic risk scores (PRSs) for psychiatric disorders and clinical and sociodemographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated single-nucleotide polymorphism heritability (h2SNP).RESULTS: Eighty-one percent of the sample initiated stimulant treatment. Within 2 years, 45% discontinued stimulants and 15% switched to nonstimulants. Bipolar disorder PRS (hazard ratio=1.05, 95% CI=1.02, 1.09) and schizophrenia PRS (hazard ratio=1.07, 95% CI=1.03, 1.11) were associated with discontinuation. Depression, bipolar disorder, and schizophrenia PRSs were marginally but not significantly associated with switch (hazard ratio range, 1.05-1.07). No associations were observed for ADHD and autism PRSs. Individuals diagnosed with ADHD at age 13 or older had higher rates of stimulant initiation, discontinuation, and switch (hazard ratio range, 1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (hazard ratio range, 0.84-0.88) and increased rates of discontinuation (hazard ratio range, 1.19-1.45) and switch (hazard ratio range, 1.40-2.08). h2SNP estimates were not significantly different from zero. No GWAS hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch.CONCLUSIONS: The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.

KW - Adolescent

KW - Adult

KW - Attention Deficit Disorder with Hyperactivity/complications

KW - Central Nervous System Stimulants/therapeutic use

KW - Child

KW - Child, Preschool

KW - Comorbidity

KW - Demography

KW - Female

KW - Genome-Wide Association Study

KW - Humans

KW - Male

KW - Mental Disorders/complications

KW - Multifactorial Inheritance

KW - Polymorphism, Single Nucleotide

KW - Risk Factors

KW - Social Factors

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1176/appi.ajp.2020.20121686

DO - 10.1176/appi.ajp.2020.20121686

M3 - Journal article

C2 - 34154395

VL - 178

SP - 854

EP - 864

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -

ID: 66788426